Home Reagents Drugs of Abuse Reagents Cannabinoid assay
Quality Guranteed Fast Delivery ad for support

Cannabinoid assay

Product Method Size Catalog Price Quantity
Cannabinoid assay Homogeneous Enzyme Immunoassay R1 2 x 16.9ml, R2 2 x 8ml DA4010 $647.20
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready-to-use
  • Assay Range
  • Working Stability 2-8 °C
    Stable to expiry
Request Kit Insert

Intended Use

The Cannabinoid assay is an in vitro diagnostic test for the qualitative and semi-quantitative detection of Cannabinoids (THC) in human urine on the RX imola and the RX daytona analysers at the 50 ng/ml cut-off. The assay is calibrated against 11-nor- Δ9-THC-9-COOH.

This assay provides only a preliminary result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgement should be exercised with any drug of abuse test result, particularly when preliminary result is positive.

Clinical Significance

The principle, active constituent in marijuana (or hashish), obtained from Cannabis Sativa plant, is the Δ1-3,4-trans tetrahydrocannabinol, frequently referred to as Δ9-tetrahydocannabinol or Δ9-THC. It is one of the most commonly used illicit drugs in the United States. Marijuana is frequently self-administered for its mood-altering properties. Chronic use has been shown to cause reversible psychological impairment, an abstinence syndrome, and can cause users to develop tolerance. At low doses, it produces mixed depressant and stimulant effects; while at higher dose it acts as a CNS depressant.

Δ9-THC is easily absorbed by inhalation (smoking) or ingestion through the gastrointestinal tract. Due to its highly fat-soluble nature Δ9-THC is readily deposited in fatty tissues, where it may remain for days or even weeks. It is primarily metabolised in the liver to a variety of compounds, the primary one being the (11-nor Δ9-THC-9-COOH). Approximately 70% of THC is excreted in faeces and urine within 72 hours of administration.


The THC immunoassay is a homogeneous enzyme immunoassay with ready-to-use liquid reagent. The assay is based on competition between drug in the sample and drug labelled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity.

In the absence of drug in the sample, Δ9-THC -labelled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. However, when free drug is present in the sample, antibody would bind to free drug; the unbound Δ9-THC -labelled G6PDH then exhibits its maximal enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.

Available Applications

RX series instruments, including:

RX daytona

RX imola